July 13, 2025 a 01:00 pm
WST: Analysts Ratings - West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. is experiencing dynamic market conditions with varied analyst sentiments. Within the diverse landscape of the pharmaceutical sector, WST has shown consistent engagement across key geographical markets. Analysts' ratings reflect a notable mix of strong buy and buy recommendations, indicating a tempered yet optimistic outlook.
Historical Stock Grades
The current analyst ratings for West Pharmaceutical Services highlight a predominantly positive sentiment. Encompassing strong buy and buy ratings, the data suggests a robust confidence in the company's market position and potential growth.
| Rating | Number of Recommendations | Score Bar |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 10 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The analysis of monthly data reveals increasing confidence in WST, particularly in the last few months. Trends show a consistent number of 'Buy' and an improvement in 'Strong Buy' ratings.
- From just 2 'Strong Buy' ratings in February 2025 to 3 in June 2025.
- 'Buy' ratings have consistently remained at 10, indicating stable positive sentiment.
- 'Hold' ratings have decreased from 3 in February to 2 in June 2025.
Percentage Trends
Recent months reflect a notable stability with sustained 'Buy' recommendations prevailing. The distribution indicates an overall bullish outlook with minimal bearish sentiment.
- June 2025 had 20% 'Strong Buy', 66.67% 'Buy', and 13.33% 'Hold'.
- No recommendations for 'Sell' or 'Strong Sell', indicating confidence in the stock.
- Shift from early 2024 where several 'Hold' ratings existed, showing improved investor confidence.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-02-14 | Overweight | Overweight | Keybanc |
| 2024-12-13 | Buy | Buy | B of A Securities |
| 2024-12-12 | Buy | Neutral | UBS |
| 2024-02-16 | Neutral | Neutral | UBS |
| 2024-02-13 | Overweight | Overweight | Keybanc |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-12-12 | Buy | Neutral | UBS |
| 2024-02-07 | Buy | Hold | Jefferies |
| 2023-06-16 | Buy | Neutral | B of A Securities |
| 2023-06-15 | Buy | Neutral | B of A Securities |
| 2023-04-11 | Overweight | Equal Weight | Stephens & Co. |
Interpretation
The market sentiment for West Pharmaceutical Services displays a stable and positive trend, underpinned by consistent high ratings of 'Buy' and 'Strong Buy'. The increased confidence in 'Strong Buy' ratings over recent months signifies growing trust in WST's market potential amidst good sector positioning. While recommendations with changes of opinion mostly reflect upgrades, no significant bearish actions are evident, suggesting minimized perceived risk.
Conclusion
In summary, West Pharmaceutical Services continues to enjoy favorable analyst outlook, highlighted by strong buy recommendations that underscore investor confidence. The notable absence of 'Sell' or 'Strong Sell' ratings further enhances this sentiment. However, the landscape remains dynamic, and much will depend on the company's ability to sustain its innovations and market presence against ongoing competitive pressures. Investors should remain vigilant yet cautiously optimistic.